文献速递消化道肿瘤与早癌

质子泵抑制剂与结直肠癌风险

Proton pump inhibitors and risk of colorectal cancer.
PubMed 文献 · Gut · 2021-07-01

基于英国临床实践研究数据链1990至2018年启动PPI或H2RA者随访至2019年的队列研究,共纳入1 293 749例PPI启动者和292 387例H2RA启动者,中位随访4.9年。PPI总体使用与结直肠癌风险无关(HR 1.02,95%CI 0.92-1.14),但风险随累积用药时长增加而升高。

要点

  • PPI总体使用与结直肠癌风险无关(HR 1.02,95%CI 0.92-1.14)。
  • 累积使用2-4年HR 1.45(95%CI 1.28-1.60),≥4年HR 1.60(95%CI 1.42-1.80)。
  • 5年和10年随访需伤害人数分别为5343和792。

核心结论

  • 与H2RA相比,任何PPI使用未增加结直肠癌风险,但长期使用可能与风险轻度增加相关。

研究设计与样本

  • 基于英国临床实践研究数据链的队列研究,纳入1990至2018年启动PPI者1 293 749例和启动H2RA者292 387例,随访至2019年,中位随访4.9年。

主要发现

  • PPI总体使用与结直肠癌风险无关(HR 1.02,95%CI 0.92-1.14)。
  • 累积使用<2年HR 0.93(95%CI 0.83-1.04),2-4年HR 1.45(95%CI 1.28-1.60),≥4年HR 1.60(95%CI 1.42-1.80)。
  • 累积剂量及治疗起始后时间也呈现相似模式。
  • 5年和10年随访需伤害人数分别为5343和792。

临床怎么用

  • 对需长期使用PPI的患者,应定期评估继续用药的必要性,并关注结直肠癌风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether proton pump inhibitors (PPIs) are associated with an increased risk of colorectal cancer, compared with histamine-2 receptor antagonists (H2RAs). DESIGN: The United Kingdom Clinical Practice Research Datalink was used to identify initiators of PPIs and H2RA from 1990 to 2018, with follow-up until 2019. Cox proportional hazards models were fit to estimate marginal HRs and 95% CIs of colorectal cancer. The models were weighted using standardised mortality ratio weights using calendar time-specific propensity scores. Prespecified secondary analyses assessed associations with cumulative duration, cumulative dose and time since treatment initiation. The number needed to harm was calculated at five and 10 years of follow-up. RESULTS: The cohort included 1 293 749 and 292 387 initiators of PPIs and H2RAs, respectively, followed for a median duration of 4.9 years. While the use of PPIs was not associated with an overall increased risk of colorectal cancer (HR: 1.02, 95% CI 0.92 to 1.14), HRs increased with cumulative duration of PPI use (<2 years, HR: 0.93, 95% CI 0.83 to 1.04; 2-4 years, HR: 1.45, 95% CI 1.28 to 1.60; ≥4 years, HR: 1.60, 95% CI 1.42 to 1.80). Similar patterns were observed with cumulative dose and time since treatment initiation. The number needed to harm was 5343 and 792 for five and 10 years of follow-up, respectively. CONCLUSION: While any use of PPIs was not associated with an increased risk of colorectal cancer compared with H2RAs, prolonged use may be associated with a modest increased risk of this malignancy.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Abrahami D, McDonald EG, Schnitzer ME, et al. Proton pump inhibitors and risk of colorectal cancer. Gut. 2021. PMID: 34210775. doi:10.1136/gutjnl-2021-325096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。